In this Review, Geary and colleagues discuss the potential mechanisms of action for all prostate cancer vaccines that trigger cytotoxic-T-lymphocyte-mediated responses and have reached clinical trials. They consider ways in which key immune events are likely to affect the efficacy of each vaccine and consider how information regarding these potential mechanisms can be exploited for future combinatorial treatments.
- Sean M. Geary
- Caitlin D. Lemke
- Aliasger K. Salem
